NEOFORDEX
Live / Registered — Registered (as of 01 Nov 2022)
What this means for you
Registered since 01 Nov 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97052171
- Registration number
- 6888402
- Mark type
- Stylized text
- Filed
- 29 Sept 2021
- Published for opposition
- 16 Aug 2022
- Registered
- 01 Nov 2022
- Attorney of record
- Pina Campagna
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, namely, amyloses, and purpura, namely, thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseases, namely, amyloses, and purpura, especially thrombocytopenic purpura
Owner
- LABORATOIRES C.T.R.S., Boulogne-Billancourt, FR
- LABORATOIRES C.T.R.S., Boulogne-Billancourt, FR
- LABORATOIRES C.T.R.S., Boulogne-Billancourt, FR
Prosecution history
- 01 Nov 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Nov 2022 — REGISTERED-PRINCIPAL REGISTER
- 16 Aug 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Aug 2022 — PUBLISHED FOR OPPOSITION
- 27 Jul 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Jul 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Jul 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Jul 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Jul 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Jul 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 05 Jul 2022 — NON-FINAL ACTION E-MAILED
- 05 Jul 2022 — NON-FINAL ACTION WRITTEN
- 29 Jun 2022 — ASSIGNED TO EXAMINER
- 27 Oct 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 02 Oct 2021 — NEW APPLICATION ENTERED